Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 501–600 of 1,000
Gastro-intestinal tract: The leading role of mucosal immunity
Steinert, A., Radulovic, K., & Niess, J. H. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14293 · Cited by 21
Modern Management of Irritable Bowel Syndrome: More Than Motility
Tack, J. F., Vanuytsel, T., & Corsetti, M. (2016) · Digestive Diseases · doi:10.1159/000445265 · Cited by 18
Corsetti, M., & Whorwell, P. J. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1298442 · Cited by 20
Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome
Wang, Y., Zheng, F., Liu, S., & Luo, H. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/9759138 · Cited by 18
“In addition, patients with nonconstipation IBS showed improvement in bloating, abdominal pain, and fecal traits after treatment with rifaximin [62], and 5-HT3 receptor antagonists can improve symptoms in IBS-D patients [63].”
Backgroundda Silva, R. B., Teixeira, R. I., Wardell, J. L., Wardell, S. M. S. V., & Garden, S. J. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02508k · Cited by 16
Chey, W. D. (2017) · Europe PMC (PubMed Central) · Cited by 17
Self-citationLim, E. C. N., & Lim, C. E. D. (2025) · Acta Microbiologica Hellenica · doi:10.3390/amh70030036 · Cited by 21
Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.
Deising, A. C., Gutiérrez, R. L., Porter, C. K., & Riddle, M. S. (2013) · Europe PMC (PubMed Central) · Cited by 16
Cai, T., Wang, X., Li, B., Xiong, F., Wu, H., & Yang, X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153527 · Cited by 16
Weerts, Z. Z. R. M., Heinen, K. G. E., Masclee, A., Quanjel, A. B. A., Winkens, B., Vork, L., Rinkens, P. E. L. M., Jonkers, D. M. A. E., & Keszthelyi, D. (2020) · JMIR mhealth and uhealth · doi:10.2196/19696 · Cited by 17
“Many high-quality IBS trials have used interactive voice response systems as the primary data collection method [28-31].”
BackgroundRegulation of Pain Perception by Microbiota in Parkinson Disease
Manjarres, Z., Calvo, M., & Pacheco, R. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000674 · Cited by 15
DuPont, H. L. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-23 · Cited by 15
“• Treatment of diarrhea-predominant IBS (55, 66).”
Alternative investigations for irritable bowel syndrome
Philpott, H., Nandurkar, S., Lubel, J. S., & Gibson, P. R. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07291.x · Cited by 16
Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
Weinstock, L. B., Geng, B., & Brandes, S. B. (2011) · PubMed · Cited by 16
Symptomatic Management of Gastroparesis
Navas, C. M., Patel, N. K., & Lacy, B. E. (2018) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2018.08.005 · Cited by 15
Novel Therapies in IBS-D Treatment
Nee, J. W., Zakari, M., & Lembo, A. J. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-015-0068-5 · Cited by 18
Self-citationTargeted therapies for diarrhea-predominant irritable bowel syndrome
Olden, K. W. (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s29023 · Cited by 16
“Of these agents, alosetron is currently the only Food and Drug Administration (FDA)-approved agent for the treatment of women with severe IBS-D.”
InfluentialMicrobiota in anorexia nervosa: potential for treatment
Landini, L., Dadson, P., Gallo, F., Honka, M., & Cena, H. (2022) · Nutrition Research Reviews · doi:10.1017/s0954422422000130 · Cited by 17
Connor, B. A. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0328-2 · Cited by 16
Correlating the Gut Microbiome to Health and Disease
Marques, T. M., Holster, S., Wall, R., König, J., Brummer, R. J., & de Vos, W. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00012-8 · Cited by 16
Wechsler, E. V., & Shah, E. D. (2021) · Drugs · doi:10.1007/s40265-021-01634-7 · Cited by 21
“The efficacy of rifaximin was shown initially in two randomized, double-blind, placebo-controlled phase 3 studies (TARGET 1 and 2), and the data supporting retreatment were shown in a later phase 3 trial (TARGET 3) [19, 20].”
BackgroundWang, K., Liu, H., Liu, J., Han, L., Zheng, K., Liang, L., Jiang, S., Meng, N., Chen, P., Qiao, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905564 · Cited by 19
“In addition, a low or free fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet was an effective therapy (Pimentel et al., 2011); however, clinicians should emphasize a balanced diet instead of a single diet.”
BackgroundKim, S. E., Kubomoto, S., Chua, K., Amichai, M. M., & Pimentel, M. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31825828a7 · Cited by 14
Self-citationMearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2017) · Atención Primaria · doi:10.1016/j.aprim.2017.01.003 · Cited by 20
Irritable bowel syndrome: current and emerging treatment options.
Peyton, L., & Greene, J. (2014) · PubMed · Cited by 21
Almansa, C., Agrawal, A. K., & Houghton, L. A. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.9 · Cited by 14
Cedillo, M. F. G., Villegas-García, F. U., Arenas-Martinez, J. S., Ornelas-Arroyo, V., Yamamoto-Furusho, J. K., Estrella-Sato, L. A., & Coss‐Adame, E. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08767-1 · Cited by 14
“The dose of rifaximin-alpha administered was not the same as that evaluated in previous studies (Target 1 and 2) [19], because the present study was a pilot study, and we chose to introduce a low dose and evaluate its potential benefit.”
Staller, K. D., Olén, O., Söderling, J. K., Roelstraete, B., Törnblom, H., Kuo, B., Nguyen, L. H., & Ludvigsson, J. F. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17736 · Cited by 17
“4 Interestingly, both antibiotics themselves 28 and faecal microbiota transplantation 29 have shown therapeutic benefit in IBS.”
BackgroundFunctional Abdominal Bloating and Gut Microbiota: An Update
Crucillà, S., Caldart, F., Michelon, M., Marasco, G., & Costantino, A. (2024) · Microorganisms · doi:10.3390/microorganisms12081669 · Cited by 15
“…in TARGET 1; 41.0% vs. 31.9%, p = 0.02, in TARGET 2; 40.2% vs. 30.3%, p < 0.001, in the two studies combined) in patients randomly taking rifaximin at a dose of 550 mg three times daily for 2 weeks, along with concurrent relief from IBS symptoms, abdominal pain, and loose or watery stools [72].”
BackgroundInfluentialCommon misconceptions and controversies in the management of irritable bowel syndrome
Black, C. J., Olano, C., Quigley, E. M. M., & Ford, A. C. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01065-9 · Cited by 14
“Although this approach was supported by large-size RCTs demonstrating a small therapeutic gain with rifaximin over placebo for global symptom end points and bloating 39,40 , these trials did not prove that success was due to eradication of SIBO 41,42 .”
Abdominal Bloating and Distension: What Is the Role of the Microbiota
Issa, B., Wafaei, N. A., & Whorwell, P. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1834-4 · Cited by 14
“Subsequently, rifaximin has become the antibiotic of choice and there is now evidence that the use of this drug over a period of 7–14 days can reduce symptoms, including gaseousness and bloating, not only in the short term but also for a period of up to 3 months [21–23].”
BackgroundGupta, A. K., & Chey, W. D. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.32 · Cited by 13
Self-citationIGUDESMAN, D. A., Sweeney, M., Carroll, I. M., Mayer‐Davis, E. J., & Bulik, C. M. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.04.003 · Cited by 15
Barberio, B., Savarino, E. V., Black, C. J., & Ford, A. C. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14279 · Cited by 13
Averyanova, Y. V., Batyrshin, E. M., Demko, A. E., Ivanova, G. Е., Ivashkin, V. T., Kostyuchenko, L. N., Викторович, Л. А., Лейдерман, И. Н., Луфт, В. М., Maev, I. V., et al. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2022-32-1-60-103 · Cited by 14
Ling, Y., Ding, L., Tian, Z., Pei, L., & Enqi, W. (2022) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000042 · Cited by 14
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review
Camilleri, M., & Dilmaghani, S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108400 · Cited by 13
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome
Kasir, R., Zakko, S. F., Zakko, P., Adler, M., Lee, A., Dhingra, S., & Guttermuth, C. F. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3872-9 · Cited by 14
“If antibiotics are used for the treatment of unselected patients with IBS, it wouldmean that more than 70 million people will receive antibiotics when less than half will respond [1].”
BackgroundResultInfluentialSelf-citationChronic, Noninfectious Diarrhea: A Review
Singh, P., Lee, A., Sheth, N. M., & Chey, W. D. (2026) · JAMA · doi:10.1001/jama.2026.0872 · Cited by 13
Self-citationPractical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome
Harris, L. A., & Heitkemper, M. M. (2012) · Gastroenterology Nursing · doi:10.1097/sga.0b013e31823ff0e8 · Cited by 12
“Results from two large, identically designed, multicenter trials of rifaximin in nonconstipated IBS were recently reported (Pimentel et al., 2011).”
BackgroundRamos, G. P., & Camilleri, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07700-8 · Cited by 15
“Two double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), with 1260 nonconstipated patients with IBS, showed adequate relief of global IBS symptoms, and improvements in bloating, abdominal pain, and stool consistency during the first 4 weeks following treatment with rifaximin, 550 mg threetimes daily for 14…”
BackgroundUpdate on the Role of Rifaximin in Digestive Diseases
Dumitrascu, D. L., Бакулин, И. Г., Berzigotti, A., Cravo, M. L., Gombošová, L., Lukáš, M., Pietrzak, A. M., Remes-Troche, J. M., Romero‐Gómez, M., Amieva‐Balmori, M., et al. (2023) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4871 · Cited by 16
Pimentel, M., Purdy, C., Magar, R., & Rezaie, A. R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.003 · Cited by 13
Self-citationTocia, C., Dumitru, I. M., Alexandrescu, L., Petcu, L. C., & Dumitru, E. (2021) · Medicine · doi:10.1097/md.0000000000024059 · Cited by 15
“Rifaximin was the treatment of choice in this study because it has proven efficacy in positively modulating the gut microbial composition,([9,10]) in particular in patients with IBS-D as demonstrated in TARGET studies.([2]) Jolley et al([11]) demonstrated that rifaximin at the dose of 1200mg/d for 10 days improved fun…”
BackgroundInfluentialLee, S., Kim, C.-R., & Kim, K.-N. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.11.004 · Cited by 12
Rifaximin Therapy of Irritable Bowel Syndrome
Koo, H. L., Sabounchi, S., Huang, D. B., & DuPont, H. L. (2012) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s7382 · Cited by 12
Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome
Shah, E. D., & Pimentel, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12692 · Cited by 12
Self-citationLu, G., Zhang, S., Wang, R., Zhang, Z., Wang, W., Wen, Q., Zhang, F., & Li, P. (2023) · Nutrients · doi:10.3390/nu15173704 · Cited by 13
Update in diagnosis and management of irritable bowel syndrome
Hung, T., Wang, C.-Y., & Lee, H. (2023) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_104_23 · Cited by 24
Fan, M., Pan, X., & Liu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s514042 · Cited by 16
Refractory inflammatory bowel disease—could it be an irritable bowel?
Meng, J., Agrawal, A., & Whorwell, P. J. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.173 · Cited by 12
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome
Scarpellini, E., Laterza, L., Ianiro, G., Tack, J. F., Abenavoli, L., & Gasbarrini, A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1182982 · Cited by 13
Irritable Bowel Syndrome and Female Patients
Harris, L. A., Umar, S. B., Baffy, N. J., & Heitkemper, M. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.02.001 · Cited by 13
He, Y., Xu, R., Wang, W., Zhang, J., & Hu, X. (2020) · Medicine · doi:10.1097/md.0000000000021502 · Cited by 15
Targeting the altered duodenal microenvironment in functional dyspepsia
Ceulemans, M., Wauters, L. I., & Vanuytsel, T. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102363 · Cited by 13
Khan, Z., Khan, S. K., Reyaz, I., Anam, H., Ijaz, O., Attique, I., Shahzad, Z., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.44807 · Cited by 14
“Pimentel, 2011 [13] Phase 3, double-blind, placebo-controlled trial (TARGET 1, TARGET 2) 309/314, 315/320 46.”
BackgroundInfluentialDrug discovery approaches to irritable bowel syndrome
Hornby, P. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1049528 · Cited by 11
“Treatment of IBS-D with rifaximin for 2 weeks was associated with significant symptomatic improvements of which 36% never relapsed over 18 -- 22 weeks of follow-up (see addendum) [77].”
BackgroundChallenges in management of irritable bowel syndrome in children
Paul, S. P., Barnard, P., Bigwood, C., & Candy, D. C. A. (2013) · Indian Pediatrics · doi:10.1007/s13312-013-0308-5 · Cited by 14
Bouchoucha, M. L., Fysekidis, M., Devroede, G. J., Raynaud, J.-J., Bejou, B., & Benamouzig, R. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12149 · Cited by 14
Talley, N. J. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.135 · Cited by 13
Enhancing High Value Care in Gastroenterology Practice
Camilleri, M., & Katzka, D. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.022 · Cited by 11
Autophagy Genes of Host Responds to Disruption of Gut Microbial Community by Antibiotics
Singh, S., Wilson, M. R., Ritz, N. L., & Lin, H. C. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4589-8 · Cited by 11
Zeiter, D. K. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.01.012 · Cited by 15
Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study
Gallo, A., Vallone, C., Sabatelli, L., Ventura, G., Covino, M., Cammarota, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1392598 · Cited by 11
“Since the features of the most of enrolled patients (elderly, often confined to bed and not able to refer about number of bowel movements), we used a previous validated scoring system based on stool consistency to assess the severity of diarrhea [21].”
Method(2009) · doi:10.4166/kjg.2019.73.2.84 · Cited by 11
Biodiversity and Industrial Applications of Genus Chaetomium
Abdel-Azeem, A. M., Abu-Elsaoud, A. M., Nahas, H. H. A., Abdel-Azeem, M. A., Balbool, B. A., Mousa, M. K., Ali, N. H., & Darwish, A. M. G. (2021) · Fungal biology · doi:10.1007/978-3-030-67561-5_5 · Cited by 13
Neurophysiologic Mechanisms of Human Large Intestinal Motility ☆
Bharucha, A. E., & Brookes, S. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00023-2 · Cited by 14
Treatment of irritable bowel syndrome with probiotics: growing evidence.
Bixquert, M. (2013) · PubMed Central · Cited by 15
Benno, P., Norin, E. L., Midtvedt, T., & Hellström, P. M. (2019) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2019.03.003 · Cited by 12
Sellin, J. H. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.027 · Cited by 11
The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Busam, J. A., Batta, N., Shah, E. D., Joo, L., Marshall, C. J., Rezaie, A. R., & Pimentel, M. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003572 · Cited by 11
Self-citationClinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome
Chuah, K. H., Loo, Q. Y., Loh, A. J. C., Leong, J. Y., Chan, W. L., Khoo, X. H., Wong, K. L., Panirsheeluam, S., Natarajan, V., Ng, A. K., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70420 · Cited by 12
“Based on previous studies on IBS, the response rates with ri-faximin and LFD were expected to be 41% [22] and 70% [16].”
New treatment options for irritable bowel syndrome with predominant diarrhea
Weber, H. C. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000302 · Cited by 10
Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome
Algera, J. P., Törnblom, H., & Simrén, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102284 · Cited by 10
Dai, Y., Shen, Z., Khachatryan, L., Vadiyan, D. E., Karampoor, S., & Mirzaei, R. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154740 · Cited by 11
Commensal bacteria: the link between IBS and IBD?
Quigley, E. M. M. (2011) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328348c033 · Cited by 13
New and Investigational Agents for Irritable Bowel Syndrome
Wadhwa, A., Camilleri, M., & Grover, M. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0473-x · Cited by 10
Yang, C., Guo, X., Ji-Li, Wei, Z., Zhao, L., Gan-ting, Z., & Sheng, S.-T. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/4078681 · Cited by 10
“Rifaximin has been approved by FDA for the therapy of IBS and was very effective in reducing the symptom of abdominal pain [16, 17].”
BackgroundAboubakr, A., & Cohen, M. S. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.08.009 · Cited by 12
Sometti, D., Ballan, C., Wang, H., Braun, C., & Enck, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-83994-4 · Cited by 11
Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
Wollny, T., Daniluk, T., Piktel, E., Wnorowska, U., Bukłaha, A., Głuszek, K., Durnaś, B., & Bucki, R. (2021) · Pathogens · doi:10.3390/pathogens10121545 · Cited by 12
“Most importantly, both improvements remained durable for the 10 weeks after cessation of the treatment [96].”
BackgroundThe role of rifaximin therapy in patients with irritable bowel syndrome without constipation
Schey, R., & Rao, S. S. C. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.50 · Cited by 10
Thoua, N. M., & Murray, C. D. (2011) · Medicine · doi:10.1016/j.mpmed.2011.01.006 · Cited by 12
Neurophysiologic Mechanisms of Human Large Intestinal Motility
Bharucha, A. E., & Brookes, S. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00036-1 · Cited by 12
Pharmacotherapy of irritable bowel syndrome
Juřica, J., & Kroupa, R. (2017) · Praktické lékárenství · doi:10.36290/lek.2017.005 · Cited by 10
Food patch testing for irritable bowel syndrome
Stierstorfer, M. B., Sha, C. T., & Sasson, M. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.09.010 · Cited by 11
Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
Zhang, S., Hong, G., Li, G., Qian, W., Jin, Y. T., & Hou, X. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02772-6 · Cited by 10
“Study has shown that rifaximin can effectively relieve symptoms such as bloating, abdominal pain, and loose or watery stools among IBS patients who did not suffer constipation [15],and it was approved for the treatment for IBS-D by FDA in 2015 [16, 17].”
BackgroundIrritable Bowel Syndrome: Current Landscape of Diagnostic Guidelines and Therapeutic Strategies
Chuy, D. S., Wi, R. S. K., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15030056 · Cited by 12
Oh, C. K., Chung, H. H., Kim, Y. J., & Kim, J. B. (2025) · Nutrients · doi:10.3390/nu17050763 · Cited by 11
Melchior, C., Hammer, H. F., Bor, S., Barba, E., Horvat, I. B., Çelebi, A., Drug, V. L., Dumitrascu, D. L., Kalkan, İ. H., Hauser, G., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70098 · Cited by 15
“D‐related bloating compared to placebo, with sustained effects for up to 3 months [272].”
Silva, K. F. E., Nanini, H. F., Cascabulho, C. M., Rosas, S. L. B., Santana, P. T., Carneiro, A. J., Anaissie, E. J., Nucci, M., & de Souza, H. S. P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i9.866 · Cited by 9
Wade, U., Pascual-Figal, D. A., Rabbani, F., Ernst, M., Albert, A., Janssens, I., Dierckxsens, Y., Iqtadar, S., Khokhar, N. A., Kanwal, A., et al. (2024) · Nutrients · doi:10.3390/nu16081204 · Cited by 11
“IBS routine care might include symptomatic drug therapies such as antispasmodics, prokinetics, laxatives, antidiarrhoeals, antibiotics, and antidepressants [21–25].”
BackgroundHow to read a clinical trial paper: a lesson in basic trial statistics.
Govani, S. M., & Higgins, P. (2012) · Europe PMC (PubMed Central) · Cited by 9
Understanding and Managing IBS and CIC in the Primary Care Setting.
Cash, B. D. (2018) · Europe PMC (PubMed Central) · Cited by 11
Targeted pharmacotherapy of irritable bowel syndrome
Arokiadoss, A., & Weber, H. C. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000618 · Cited by 10
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline
Jones, J. R. A., Lembo, A. J., Heidelbaugh, J. J., Kuritzky, L., & Lacy, B. E. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1888705 · Cited by 13
Self-citationMicrobiome and paediatric gut diseases
Gerasimidis, K., Gkikas, K., Stewart, C. J., Neelis, E. G., & Svolos, V. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320875 · Cited by 10
The Potential Role of Human Milk Oligosaccharides in Irritable Bowel Syndrome
Morales, P. S., Wijeyesekera, A., Robertson, M. D., Jackson, P. P. J., & Gibson, G. R. (2022) · Microorganisms · doi:10.3390/microorganisms10122338 · Cited by 11
“Antibiotic treatment has been deemed safe for IBS-D, with mixed response regarding bloating, abdominal pain and stool consistency [55].”
BackgroundThe Role of Microbiota in Upper and Lower Gastrointestinal Functional Disorders
Mandarino, F. V., Sinagra, E., Raimondo, D., & Danese, S. (2023) · Microorganisms · doi:10.3390/microorganisms11040980 · Cited by 11
“On the other hand, rifaximin has shown benefits in non-C-IBS [24], and there is optimism regarding its use in C-IBS [25,26].”
BackgroundIrritable Bowel Syndrome in Women
Roisinblit, K. C. (2012) · Journal of Midwifery & Women s Health · doi:10.1111/j.1542-2011.2012.00200.x · Cited by 13
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.